Abstract
Acquired deficiency of C1 inhibitor (C1-INH) with angioedema symptoms (acquired angioedema, AAE) is characterized by local increase in vascular permeability (agioedema) of the skin and the gastrointestinal and oro-pharyngo-laryngeal mucosa. The mediator of symptoms is bradykinin, a potent vasoactive peptide, released from high molecular weight kininogen when it is cleaved by plasma kallikrein a serine protease controlled by C1-INH. Autoantibodies inactivating C1-INH are detected in the majority of patients and account for the deficiency. Irrespectively to the presence of anti-C1-INH autoantibodies lymphoproliferative diseases, ranging from benign monoclonal gammopathies to malignant lymphoma, are frequently associated with AAE. Demonstration that monoclonal components correspond to anti-C1-INH autoantibodies and correlation between course of lymphoma and course of AAE provide strong support to consider the two diseases expression of the same pathologic process.
Keywords: Angioedema, C1 inhibitor, lymphoma, autoimmunity, vascular permeability, bradykinin, contact system
Current Molecular Medicine
Title: The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema
Volume: 10 Issue: 4
Author(s): M. Cicardi and A. Zanichelli
Affiliation:
Keywords: Angioedema, C1 inhibitor, lymphoma, autoimmunity, vascular permeability, bradykinin, contact system
Abstract: Acquired deficiency of C1 inhibitor (C1-INH) with angioedema symptoms (acquired angioedema, AAE) is characterized by local increase in vascular permeability (agioedema) of the skin and the gastrointestinal and oro-pharyngo-laryngeal mucosa. The mediator of symptoms is bradykinin, a potent vasoactive peptide, released from high molecular weight kininogen when it is cleaved by plasma kallikrein a serine protease controlled by C1-INH. Autoantibodies inactivating C1-INH are detected in the majority of patients and account for the deficiency. Irrespectively to the presence of anti-C1-INH autoantibodies lymphoproliferative diseases, ranging from benign monoclonal gammopathies to malignant lymphoma, are frequently associated with AAE. Demonstration that monoclonal components correspond to anti-C1-INH autoantibodies and correlation between course of lymphoma and course of AAE provide strong support to consider the two diseases expression of the same pathologic process.
Export Options
About this article
Cite this article as:
Cicardi M. and Zanichelli A., The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema, Current Molecular Medicine 2010; 10 (4) . https://dx.doi.org/10.2174/156652410791317066
DOI https://dx.doi.org/10.2174/156652410791317066 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunotherapy for Food Allergies in Children
Current Pharmaceutical Design Intravenous Immunoglobulin as a Potential Therapy for Refractory Urticaria - A Review
Inflammation & Allergy - Drug Targets (Discontinued) Small Peptides as Modulators of Serine Proteases
Current Medicinal Chemistry Neuro-AIDS: Current Status and Challenges to Antiretroviral Drug Therapy (ART) for Its Treatment
Current Drug Therapy Plastid Molecular Pharming II. Production of Biopharmaceuticals by Plastid Transformation
Mini-Reviews in Medicinal Chemistry The Effects of Dehydroepiandrosterone (DHEA) in the Treatment of Depression and Depressive Symptoms in Other Psychiatric and Medical Illnesses: A Systematic Review
Current Drug Targets Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Deciphering Dual Antiplatelet Therapy in the Era of Drug-Eluting Coronary Stents
Current Drug Targets Filariasis: Current Status, Treatment and Recent Advances in Drug Development
Current Medicinal Chemistry Efalizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry State of the Art and Perspectives in Food Allergy (Part I): Diagnosis
Current Pharmaceutical Design Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension
Current Vascular Pharmacology Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Current Vascular Pharmacology Hypersensitivity to Hymenoptera Venom: Advances in Diagnosis and Implications for Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Parvalbumin as a Pleomorphic Protein
Current Protein & Peptide Science Food Allergy
Current Pharmaceutical Design Editorial (Mini-Thematic Issue: Mold Allergens and Antigenic Epitopes Correlation with Fungal Diseases)
Current Protein & Peptide Science Complement Activation-Related Pseudoallergy Caused by Amphiphilic Drug Carriers: The Role of Lipoproteins
Current Drug Delivery Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry